We are preparing the requested document. Please wait, this may take a while...!
|Application / Reactivity||Human|
|ELISA (Capture)||1 Antibodies|
|Enzyme Immunoassay (EIA)||9 Antibodies|
|Flow Cytometry (FACS)||11 Antibodies|
|Immunochromatography (IC)||1 Antibodies|
|Immunocytochemistry (ICC)||3 Antibodies|
|Immunofluorescence (IF)||11 Antibodies|
|Immunofluorescence (Paraffin-embedded Sections) (IF (p))||22 Antibodies|
|Immunohistochemistry (IHC)||49 Antibodies|
|Immunohistochemistry (Frozen Sections) (IHC (fro))||5 Antibodies|
|Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))||27 Antibodies|
|Immunoprecipitation (IP)||19 Antibodies|
|Intracellular Flow Cytometry (ICFC)||2 Antibodies|
|Western Blotting (WB)||99 Antibodies|
|Antigen||Fms-Related Tyrosine Kinase 4 (FLT4) Antibodies|
|Conjugate||This FLT4 antibody is conjugated to APC Alternatives|
Flow Cytometry (FACS), Intracellular Flow Cytometry (ICFC)
|7 references available|
|Supplier||Log in to see|
Product Details anti-FLT4 AntibodyTarget Details FLT4 Application Details Handling References for anti-FLT4 Antibody (ABIN2658417) Images
|Purification||The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions. The solution is free of unconjugated APC and unconjugated antibody.|
Target Details FLT4Product Details anti-FLT4 Antibody Application Details Handling References for anti-FLT4 Antibody (ABIN2658417) Images back to top
|Alternative Name||VEGFR-3 (FLT4 Antibody Abstract)|
|Background||Receptor tyrosine Kinase VEGFR-3, also known as FLT4, together with VEGFR1 (FIT1) and VEGFR2 (KDR/Flk-1), are the receptors for vascular endothelial growth factors (VEGF). The VEGFR family belongs to the class II subfamily of receptor tyrosine kinases (RTKs), containing a large extracellular region which is composed of seven Ig-like domains (D1-D7), a single transmembrane, helix, and a cytoplasmic region with tyrosine kinase activity. In VEGFR-3, the fifth Ig homology domain is proteolytically cleaved which results in polypeptides that remain linked by two disulfide bonds. VEGFR-3 is widely expressed on all endothelial cells in early embryogenesis, while, in adult tissues, VEGFR-3 expression disappears from the vascular endothelial cells and is observed only on the lymphatic endothelium. VEGF-C and VEGF-D activation of VEGFR-3 plays an important role in the formation of the lymphatic vessel system. Aberrant activation or expression of VEGFR and their ligands has been implicated in tumor angiogenesis, coronary artery disease, diabetic blindness, and other diseases.|
Application DetailsProduct Details anti-FLT4 Antibody Target Details FLT4 Handling References for anti-FLT4 Antibody (ABIN2658417) Images back to top
|Application Notes||Optimal working dilution should be determined by the investigator.|
|Restrictions||For Research Use only|
HandlingProduct Details anti-FLT4 Antibody Target Details FLT4 Application Details References for anti-FLT4 Antibody (ABIN2658417) Images back to top
|Buffer||Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .|
|Precaution of Use||This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.|
|Handling Advice||Protect from prolonged exposure to light. Do not freeze.|
|Storage Comment||The antibody solution should be stored undiluted between 2°C and 8°C.|
References for anti-FLT4 Antibody (ABIN2658417)Product Details anti-FLT4 Antibody Target Details FLT4 Application Details Handling Images back to top
Tammela, Zarkada, Wallgard et al.: "Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. ..." in: Nature, Vol. 454, Issue 7204, pp. 656-60, 2008 (PubMed).
Kilic, Oliveira-Ferrer, Neshat-Vahid et al.: "Lymphatic reprogramming of microvascular endothelial cells by CEA-related cell adhesion molecule-1 via interaction with VEGFR-3 and Prox1." in: Blood, Vol. 110, Issue 13, pp. 4223-33, 2007 (PubMed).
Partanen, Arola, Saaristo et al.: "VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues." in: FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Vol. 14, Issue 13, pp. 2087-96, 2000 (PubMed).
Folpe, Veikkola, Valtola et al.: "Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type ..." in: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, Vol. 13, Issue 2, pp. 180-5, 2000 (PubMed).
Valtola, Salven, Heikkilä et al.: "VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer." in: The American journal of pathology, Vol. 154, Issue 5, pp. 1381-90, 1999 (PubMed).
Jussila, Valtola, Partanen et al.: "Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3." in: Cancer research, Vol. 58, Issue 8, pp. 1599-604, 1998 (PubMed).
Galland, Karamysheva, Mattei et al.: "Chromosomal localization of FLT4, a novel receptor-type tyrosine kinase gene." in: Genomics, Vol. 13, Issue 2, pp. 475-8, 1992 (PubMed).
ImagesProduct Details anti-FLT4 Antibody Target Details FLT4 Application Details Handling References for anti-FLT4 Antibody (ABIN2658417) back to top